Business
Stevia Corp. Files Two Additional Provisional Patent Applications With the United States Patent and Trademark Office for a Cannabidiol (CBD) and Aspirin Formulation and a Cannabidiol and Naproxen Formulation to Treat Pain and Cardiovascular Disease
Stevia Corp. Files Two Additional Provisional Patent Applications With the United States Patent and Trademark Office for a Cannabidiol (CBD) and Aspirin Formulation and a Cannabidiol and Naproxen Formulation to Treat Pain and Cardiovascular Disease.
About this update from Stevia Corp.
[{"type":"text","content":"\n \n \n Stevia Corp. Files Two Additional Provisional Patent Applications With the United States Patent and Trademark Office for a Cannabidiol (CBD) and Aspirin Formulation and a Cannabidiol and Naproxen Formulation to Treat Pain and Cardiovascular Disease\n \n \nStevia Corp. Files Two Additional Provisional Patent Applications With the United States Patent and Trademark Office for a Cannabidiol (CBD) and Aspirin Formulation and a Cannabidiol and Naproxen Formulation to Treat Pain and Cardiovascular Disease\n \n INDIANAPOLIS, IN--(Marketwired - Jan 29, 2015) - Stevia Corp. (OTCQB: STEV) (\"Stevia Corp\" or the \"Company\"), an international farm management company and healthcare company focused on the commercial development of products that support a healthy lifestyle, including stevia and hemp and their compounds, is pleased to announce the filing of two additional provisional patent applications with the United States Patent and Trademark Office (USPTO) for the treatment of pain and cardiovascular disease. The two separate applications include a provisional patent application that contains a formulation of naproxen and cannabidiol (CBD) and another application that contains a formulation of aspirin and cannabidiol. Stevia Corp. has now filed four provisional patent applications with the USPTO for four of the largest selling generic pain killing medications worldwide in combination with CBD.\n \"We believe that there will be significant advantages of using these four very effective drugs in combination with cannabidiol as opposed to using these drugs alone. Acetaminophen, Ibuprofen, Naproxen and Aspirin generate billions of dollars in sales each year. Our four provisional patent applications include 63 claims in total and we look forward to filing the utility patents over the next 12 months. We strongly believe that our intellectual property strategy, if successfully implemented, will provide us a competitive advantage over other healthcare companies using cannabinoids for human healthcare,\" commented George Blankenbaker, President of Stevia Corp.\n Mr. Blankenbaker concluded, \"We have included other cannabinoids within our 63 patent claims including THC which we believe may also create significant value going forward.\"\n All four provisional patent applications were filed with the assistance of an intellectual property att...